Sandoz reportedly appoints generics unit CEO
Novartis's Sandoz generics unit has a new leader.
The Pharma Letter reported this week that Richard Saynor has been named the new CEO of the division. He takes over for Richard Francis, who departed the company in March,
Saynor has 20 years of experience in generics and pharmaceutical brands within the industry, having previously served as the senior vice president for classic and established products, commercial and digital platforms at GlaxoSmithKline, according to the report.
Prior to GSK, he held commercial operations leadership roles at Sandoz and oversaw the expansion of its generics business across Asia, Latin America and Turkey. In addition, he is expected to become a member of Novartis’ executive committee, the report said.
The Pharma Letter reported this week that Richard Saynor has been named the new CEO of the division. He takes over for Richard Francis, who departed the company in March,
Saynor has 20 years of experience in generics and pharmaceutical brands within the industry, having previously served as the senior vice president for classic and established products, commercial and digital platforms at GlaxoSmithKline, according to the report.
Prior to GSK, he held commercial operations leadership roles at Sandoz and oversaw the expansion of its generics business across Asia, Latin America and Turkey. In addition, he is expected to become a member of Novartis’ executive committee, the report said.